Industry & Regulation
How regulatory and business changes ripple down to patients — FDA proposals, warning letters, advisory committee reviews, and what major telehealth pivots tell us about access and cost.
13 articles
Industry & Regulation
Wegovy's $199 starter price ends June 30: what's next
Wegovy's introductory $199/month NovoCare savings offer for injectable starter doses expires after June 30, 2026. Here's what current patients face on July 1 and what options exist.
5 min · Updated 2026-07-06
Industry & Regulation
The FDA is reviewing 7 peptides for the compounding list. Here's what that actually means.
The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review BPC-157, TB-500, and 5 other peptides for the 503A Bulks List. Here's what that process actually involves — and what it doesn't.
4 min · Updated 2026-06-17
Industry & Regulation
'Peptides are legal again' — what the reclassification actually means
HHS announced that 12 peptides would move off the FDA's restricted compounding list. Here's what the April 2026 regulatory action actually changed — and what it didn't.
5 min · Updated 2026-06-17
Industry & Regulation
ADA 2026: the GLP-1 and obesity findings that matter for patients
The ADA 86th Scientific Sessions (June 5-8, New Orleans) produced notable GLP-1 data. Here's what matters — and what remains under investigation.
4 min · Updated 2026-06-13
Industry & Regulation
GLP-1 pricing in 2026: what you'll actually pay
GLP-1 list prices start around $1,300–$1,400 per month, but what you pay depends on insurance, savings programs, and access type. Here's how the pricing…
5 min · Updated 2026-06-08
Industry & Regulation
503A vs 503B compounding: what the FDA rules mean for GLP-1…
Two types of compounding pharmacies face very different FDA rules. If you have been on a compounded GLP-1 and are confused about what is still legal in 2026…
6 min · Updated 2026-06-08
Industry & Regulation
Medicare's GLP-1 Bridge starts July 1. Here's who qualifies…
Starting July 1, 2026, eligible Medicare Part D beneficiaries can access certain GLP-1 medications for $50 per month. Here's how the program works and who…
8 min · Updated 2026-06-08
Industry & Regulation
Cigna is dropping GLP-1 coverage. Here's what patients…
Health insurer Cigna will stop covering GLP-1 weight-loss drugs for its own employees on July 1. Here's what the employer coverage pullback means for patients.
7 min · Updated 2026-06-08
Industry & Regulation
FDA warned 30 telehealth companies over GLP-1 claims. Here's what they got wrong.
The FDA issued 30 warning letters to telehealth companies on March 3, 2026 for false or misleading claims about compounded GLP-1 products. What the violations were and how to evaluate what you're being sold.
5 min · Updated 2026-05-28
Industry & Regulation
What the Hims & Hers GLP-1 pivot tells patients about access and cost
Hims & Hers posted a $92M Q1 2026 loss as it wound down its compounded GLP-1 supply chain and pivoted to branded Wegovy and Zepbound. Here's what the shift means for patients who relied on lower-cost compounded options.
4 min · Updated 2026-05-27
Industry & Regulation
What the FDA's 503B removal proposal means for compounded GLP-1 patients
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B compounding list on April 30, 2026. Here's what that actually means — and what it doesn't.
4 min · Updated 2026-05-27
Industry & Regulation
The ProRx FDA warning letter: what compounded GLP-1 patients need to understand
The FDA issued warning letter WL #723704 to ProRx LLC on April 7, 2026, citing illegal tirzepatide compounding and serious sterility failures. Here's what it means.
5 min · Updated 2026-05-27
Industry & Regulation
FDA's April 2026 GLP-1 compounding clarification: what it says and what it means
The FDA's April 1, 2026 clarification restricts compounded semaglutide+B12 combinations and limits 503A pharmacies to 4 prescriptions per month of such products. Here's what the policy actually says.
4 min · Updated 2026-05-27